GLP1R and obstructive sleep apnea syndrome: Recent advances in pharmacological therapies, particularly with incretin-based agents such as GLP-1 RAs, have shown significant potential not only for weight reduction but also for improving metabolic and respiratory parameters in OSA (108, 145, 146).